JPW/GJG/YFL

Docket No. 0575/54805

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231
BOX: PATENT APPLICATION

September 29, 1999

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Howard J. Worman & Naoto Mamiya for
Inventor(s)

HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION
Title of Invention

Also enclosed are:

X 8 sheet(s) of ____informal X formal drawings.

____ Oath or declaration of Applicant(s).

____ A power of attorney

____ An assignment of the invention to _____

X A Preliminary Amendment

X A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE SMALL ENTITY	RATE OTHER ENTITY		FEE SMALL ENTITY	FEE OTHER ENTITY
Total Claims	30 -20	=	10	X	$ 9.00	$18.00	=	$ 90	$
Independent Claims	3 -3	=	0	X	$39.00	$78.00	=	$ 0	$
Multiple Dependent Claims Presented: ____Yes X No					$130.00	$260.00	=	$ 0	$
						BASIC FEE		$ 380	$ 760
						TOTAL FEE		$ 470	$

*If the different in Col. 1 is less than zero, enter "0" in Col. 2

Applicants: Howard J. Worman & Naoto Mamiya
Serial No: Not Yet Known
Filed: Herewith

Letter of Transmittal
Page 2

__X__ A check in the amount of $ 470 to cover the filing fee.

____ Please charge Deposit Account No. _____ in the amount of $_____.

__X__ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

__X__ Filing fees under 37 C.F.R. §1.16.

__X__ Patent application processing fees under 37 C.F.R. §1.17.

____ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

__X__ Three copies of this sheet are enclosed.

____ A certified copy of previously filed foreign application No. _____ _____ filed in _____ on _____. Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

__X__ Other (identify) Express Mail Certificate of Mailing Bearing Label No. EL066381049US, dated September 29, 1999

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Applicant or Patentee: Howard J. Worman et al. Attorney's Docket No: JPW/GJG/YFL 0575/54805
Serial or Patent No.: Not Yet Known
Filed or Issued: Herewith
Title of Invention or Patent: HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9(f)
AND §1.27(d) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: The Trustees of Columbia University in the City of New York

Address of Organization: 110 Low Memorial Library, West 116th Street & Broadway New York, NY 10027

TYPE OF ORGANIZATION:

X UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
____ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3)
____ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____
____ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3) IF LOCATED IN THE UNITED STATES OF AMERICA
____ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. §1.9(e)* for purposes of paying reduced fees under 35 U.S.C. §41(a) and 41(b), with regard to the invention entitled HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

by inventor(s) Howard J. Worman et al.

described in:

X the specification filed herewith
____ application serial no. _____ filed _____
____ patent no. _____ issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive each individual, concern, or organization known to have rights to the invention is listed below[a] and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(d)* or a nonprofit organization under 37 C.F.R. 1.9(e)*

[a]NOTE: Separate verified statements are required from each person, concern, or organization having rights to the invention averring to their status as small entities. 37 C.F.R. §1.27.

Name: **NONE**
Address: _____

____ Individual ____ Small Business Concern ____ Nonprofit Organization

37 C.F.R. §§1.9(d), 1.9(e)

(d) A small business concern as used in this chapter means any business concern as defined by the Small Business Administration in 13 C.F.R. §121.3-18, published on September 30, 1982 at 47 FR 43273. For the convenience of the users of these regulations, that definition states:

§121.3-18 Definition of small business for paying reduced patent fees under Title 35, U.S. Code.

(a) Pursuant to Pub. L. 97-247, a small business concern for purposes of paying reduced fees under 35 U.S. Code 41(a) and (b) to the Patent and Trademark Office means any business concern (1) whose number of employees, including those of its affiliates, does not exceed 500 persons and (2) which has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section. For the purpose of this section concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. The number of employees of the business concern is the average over the fiscal year of the the persons employed during each of the pay periods of the fiscal year. Employees are those persons employed on a full-time, part-time or temporary basis during the previous fiscal year of the concern.

(b) If the Patent and Trademark Office determines that a concern is not eligible as a small business concern within this section, the concern shall have a right to appeal that determination to the Small Business Administration. The Patent and Trademark Office shall transmit its written decision and the pertinent size determination file to the SBA in the event of such adverse determination and size appeal. Such appeals by concerns should be submitted to the SBA at 1441 L Street, NW., Washington, D.C. 20416 (Attention: SBA Office of General Counsel). The appeal should state the basis upon which it is claimed that the Patent and Trademark Office initial size determination on the concern was in error; and the facts and arguments supporting the concern's claimed status as a small business concern under this section.

(e) A nonprofit organization as used in this chapter means (1) a university or other institution of higher education located in any country; (2) an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)(3)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)); (3) any nonprofit scientific or educational organization qualified under a nonprofit organization statute of a state of this country (35 U.S.C. 201(i); or (4) any nonprofit organization located in a foreign country which would qualify as a nonprofit organization under paragraphs (e)(2) or (3) of this section if it were located in this country.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. §1.28(b)*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: Mr. Jack M. Granowitz
Title In Organization: Executive Director, Columbia Innovation Enterprise
Address: Engineering Terrace - Suite 363, Amsterdam and 120th Street
New York, New York 10027
Signature: Jack M. Granowitz
Date Of Signature: June 30, 1999

*See Reverse

37 C.F.R. §1.28(b)

(b) Once status as a small entity has been established in an application or patent, fees as a small entity may thereafter be paid in that application or patent without regard to a change in status until the issue fee is due or any maintenance fee is due. Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application or patent prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate pursuant to §1.9 of this part. The notification of change in status may be signed by the applicant, any person authorized to sign on behalf of the assignee, or an attorney or agent of record or acting in a representative capacity pursuant to §1.34(a) of this part.

Dkt. 54805/JPW/GJG/YFL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Howard J. Worman and Naoto Mamiya
U.S. Ser. No.	:	Not Yet Known
Filing Date	:	Herewith
For	:	HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

1185 Avenue of the Americas
New York, New York 10036
September 29, 1999

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims

Please cancel claims 31-43 without prejudice.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fees are required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Application
for
United States Letters Patent

To all whom it may concern:

Be it known that

Howard J. Worman and Naoto Mamiya

have invented certain new and useful improvements in

HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

of which the following is a full, clear and exact description.

HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed numerically at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

Background of the Invention

Chronic hepatitis C is a major public health problem and one of the leading worldwide causes of chronic liver disease, cirrhosis and hepatocellular carcinoma (1). Approximately 4 million Americans are chronically infected with hepatitis C virus and as many as 25% of them may eventually develop cirrhosis (2). End-stage liver disease from hepatitis C is now the leading indication for orthotopic liver transplantation in the United States. Hepatitis C virus was identified in 1989 and demonstrated to be the major cause of what was then referred to as non-A, non-B hepatitis (3, 4). Despite major advances in diagnosing chronic hepatitis C and screening the blood supply since that time, almost nothing is known about how the virus infects, kills or transforms cells. For this reason, current therapeutic options are limited and new agents have been difficult to develop.

According to a recent National Institutes of Health Consensus Development Conference Panel Statement on the Management of Hepatitis C (5), there is an urgent need for

effective antiviral therapeutics capable of inhibiting hepatitis C virus replication and stopping or delaying the progression of liver disease. The Panel also concluded that a major bottleneck to the drug discovery process is the absence of a readily available cell culture system that is fully permissive for viral replication. A small animal model of hepatitis C virus infection is also lacking. For these reasons, novel, alternative approaches must be developed to identify targets for the design of therapeutic agents for the treatment of patients with chronic hepatitis C.

The development of specific drugs against hepatitis C virus has been impeded because there is no non-primate animal model of infection and all attempts to culture the virus have failed. Currently, only non-specific antiviral agents have been used to treat patients with chronic hepatitis C. The only currently approved drugs in the United States are preparations of interferon-alpha and ribavirin. The long-term cure rate of subjects treated with interferon-alpha is less than 10%. The use of ribavirin, in combination with interferon-alpha, has shown slightly better long-term cure, however, still in only a minority of subjects.

Hepatitis C virus is a positive single stranded RNA virus and a member of the *Flavivaridae* family (3,6-10). Once hepatitis C virus infects cells, the positive, single-stranded RNA genome is translated into a polyprotein of 3010 to 3033 amino acids, depending upon the strain (6-9). The viral RNA is not capped and translation occurs via internal ribosome entry sites (10,11). The mechanism of translation from uncapped viral RNA therefore differs from that used by virtually all cellular mRNAs which are capped at their 5' ends.

The hepatitis C virus polyprotein is proteolytically processed by both host cell and viral proteases into several smaller polypeptides (6-9,12) (Figure 1). The major structural proteins are a core protein and two envelope proteins (E1 and E2). Four major non-structural proteins called NS2, NS3, NS4, and NS5, are also generated, two of which, NS4 and NS5, are further processed into smaller polypeptides called NS4A, NS4B, NS5A, and NS5B. The non-structural proteins have various enzymatic activities, such as RNA helicase (NS3), protease (NS2, NS3-NS4A complex) and RNA polymerase (NS5B). NS5A has been implicated in determining sensitivity to interferon.

The hepatitis C virus envelope proteins E1 and E2 interact with hepatocyte plasma membrane proteins that likely mediate the entry of the virus into cells. E2 has been shown to bind to the plasma membranes of cultured cells (13). E1 and E2 may form a heteromeric complex (14) and their association may be necessary for virus binding to cells and for their entry into cells. However, cell surface proteins that function as hepatitis C virus receptors or co-receptors by binding to E1 and E2 have not been identified.

Summary of the Invention

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of inhibiting the attachment of hepatitis C virus onto cells by specifically binding to the hepatitis C virus envelope E2 protein so as to treat or prevent hepatitis C virus infection.

The present invention also provides a method of identifying a compound which can inhibit the attachment of hepatitis C virus onto cells by inhibiting the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus binding to cells and their entry into cells, comprising (a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein under a suitable reaction conditions, (b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and (c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus onto cells.

The present invention further provides a method for determining whether a compound can be used for treating or preventing hepatitis C virus infection in a subject, wherein said compound inhibits the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus attachment onto cells so as to

block the attachment of hepatitis C virus into cells, comprising (a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein or its variant under a suitable reaction conditions, (b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and (c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus onto cells.

Brief Description of the Figures

Figure 1. Diagram of the major processed proteins encoded by the hepatitis C virus genome. The 3010-3033 amino acid polyprotein is processed into several smaller polypeptides. Core, E1 and E2 are structural polypeptides. Core protein is the virus nucleocapsid and E1 and E2 are viral envelope proteins. The major non-structural proteins are NS2, NS3, NS4 and NS5. NS4 is further processed into NS4A and NS4B and NS5 into NS5A and NS5B. NS2 and part of NS3 are proteases that process the viral polyprotein. NS3 also has RNA-helicase activity. NS4A is a cofactor for the NS3 protease and NS5B is an RNA-dependent, RNA polymerase. The functions of NS4B and NS5A are less-well understood but NS5A is thought to play a role in determining sensitivity to interferon.

Figure 2. Amino acid sequence of protein Eo (SEQ ID NO:1), identified in the yeast two-hybrid assay, that binds to hepatitis C virus envelope protein E2.

Figure 3. Binding of Eo to a portion of hepatitis C virus envelope protein E2 (SEQ ID NO:3) in the yeast two-hybrid assay. The left filter shows yeast colonies co-transformed with a plasmid that encodes a portion of hepatitis C virus E2 fused to the DNA binding domain of GAL4 and a plasmid that encodes a portion of Eo fused to the transcriptional activation domain of GAL4. The colonies give strong β-galactosidase activity (blue; gray in this copy) that is induced by a protein-protein interaction. In contrast, no β-

galactosidase activity is seen in yeast transformed with a portion of Eo alone fused to the transcription activation domain of GAL4 (middle filter) or the Eo fusion protein and a fusion of the DNA binding domain of GAL4 and lamin C (right filter).

Figure 4. Kyte-Doolittle hydropathy analysis of Eo. The putative transmembrane segment is indicated by *.

Figure 5. Kyte-Doolittle hydropathy analysis of Eo is shown at top with the putative transmembrane segment indicated by *. Below, the amino acids in Eo, Eo1 and Eo2 are indicated.

Figure 6. Binding of Eo1 to a portion of hepatitis C virus envelope protein E2 in the yeast two-hybrid assay. The left filter (Eo) shows yeast colonies co-transformed with a plasmid that encodes a portion of Eo fused to the transcriptional activation domain of GAL4. The colonies give strong β-galactosidase activity (blue; gray in this copy) that is induced by a protein-protein interaction. The middle filter (Eo1) shows yeast colonies co-transformed with a plasmid that encodes a portion of hepatitis C virus E2 fused to the DNA binding domain of GAL4 and a plasmid that encodes a portion of hepatitis C virus E2 fused to the DNA binding domain of GAL4 and a plasmid that encodes amino acids 1 to 120 of Eo (Eo1) fused to the transcriptional activation domain of GAL4. The colonies give a weaker β-galactosidase activity (blue; gray in this copy) that is induced by a

protein-protein interaction. In contrast, no β-galactosidase activity is seen in yeast transformed with control plasmids (right filter).

Figure 7. Amino acid sequence of E2 protein (SEQ ID NO:2), identified as amino acids 384-746 in Figure 1 of reference 7.

Figure 8. Amino acid sequence of a water soluble variant of E2 protein E2 (SEQ ID NO:3), identified as amino acids 406-660 in Figure 1 of reference 7.

Detailed Description of the Invention

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of inhibiting the attachment of hepatitis C virus onto cells by specifically binding to the hepatitis C virus envelope E2 protein so as to treat or prevent hepatitis C virus infection.

Variants in amino acid sequence of hepatitis C virus envelope E2 protein are produced when one or more amino acids in naturally occurring hepatitis C virus envelope E2 protein is substituted with a different natural amino acid, an amino acid derivative, a synthetic amino acid, an amino acid analog or a non-native amino acid. Particularly preferred variants include homologous hepatitis C virus envelope E2 protein. Variants of a hepatitis C virus envelope E2 protein may include biologically active fragments of naturally occurring hepatitis C virus envelope E2 protein, wherein sequences of the variant differ from the wild type hepatitis C virus envelope E2 protein sequence by one or more conservative amino acid substitutions. Such substitutions typically would have minimal influence on the secondary structure and hydrophobicity of hepatitis C virus envelope E2 protein.

Variants in amino acid sequence of Eo protein are produced when one or more amino acids in naturally occurring Eo protein is substituted with a different natural amino acid, an amino acid derivative, a synthetic amino acid, an amino acid analog or a non-native amino acid. Particularly preferred variants include homologous Eo protein. Variants of an Eo protein may include

biologically active fragments of naturally occurring Eo protein, wherein sequences of the variant differ from the wild type Eo protein sequence by one or more conservative amino acid substitutions. Such substitutions typically would have minimal influence on the secondary structure and hydrophobicity of Eo protein. The amino acid sequences of Eo protein has been determined to have SEQ ID NO:1 in Figure 2 and the amino acid sequence of one variant of Eo protein has been determined to be amino acids 1-120 of SEQ ID NO:1.

"Polypeptide" includes both peptides and proteins. "Peptide" means a polypeptide of fewer than 10 amino acid residues in length, and "protein" means a polypeptide of 10 or more amino acid residues in length. In this invention, the polypeptides may be naturally occurring or recombinant (i.e. produced via recombinant DNA technology), and may contain mutations (e.g. point, insertion and deletion mutations) as well as other covalent modifications (e.g. glycosylation and labeling via biotin, streptavidin, fluoracine, and radioisotopes such as ^{131}I). Moreover, each instant composition may contain more than a single polypeptide, i.e. each may be a monomer (one polypeptide bound to a polymer) or a multimer (two or more polypeptides bound to a polymer or to each other).

As used herein, "effective amount" means an amount of a compound which interrupts the binding between hepatitis C virus E2 protein and a cellular protein, which can inhibit the hepatitis C virus attachment onto cells and can be determined using methods well known to those skilled in the art.

In one embodiment of the method, the agent is a

polypeptide, a pseudo enzyme, a peptidomimetic compound, a nucleic acid, an antibody or its variant thereof.

In another embodiment of the method, the cells are liver cells.

In another embodiment of the method, the liver cells are human liver cells.

In another embodiment of the method, the hepatitis C virus E2 protein comprises amino acid sequence of Figure 7, SEQ ID NO:2.

In another embodiment of the method, the variant of the hepatitis C virus envelope E2 protein comprises 254 amino acids of said hepatitis C virus envelope E2 protein of SEQ ID NO:2.

In another embodiment of the method, the variant of the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 8, SEQ ID NO:3.

In another embodiment of the method, the agent comprises a Eo protein or its variant.

In another embodiment of the method, the Eo protein comprises the amino acid sequence of Figure 2, SEQ ID NO:1.

In yet another embodiment of the method, the variant of Eo protein comprises 120 amino acids of SEQ ID NO:1.

In a further embodiment of the method, the variant of Eo protein comprises Eo1 protein having amino acids 1-120 of SEQ ID NO:1.

The present invention also provides a method of identifying a compound which can inhibit the attachment of hepatitis C virus into cells by inhibiting the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells, comprising (a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein or its variant under a suitable reaction conditions, (b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and (c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus onto a cell.

In one embodiment of the method, the cell is in a subject.

In another embodiment of the method, the subject is a mammal.

In another embodiment of the method, the subject is a human.

In another embodiment of the method, the cells are liver cells.

In another embodiment of the method, the liver cells are human liver cells.

In another embodiment of the method, the cellular protein

comprises Eo protein or its variant.

In another embodiment of the method, the Eo protein comprises the amino acid sequence of Figure 2, SEQ ID NO:1.

In another embodiment of the method, the variant of Eo protein comprises 120 amino acids of SEQ ID NO:1.

In another embodiment of the method, the variant of Eo protein comprises Eo1 protein having amino acids 1-120 of SEQ ID NO:1.

In another embodiment of the method, the hepatitis C virus E2 protein comprises amino acid sequence of Figure 7, SEQ ID NO:2.

In another embodiment of the method, the variant of the hepatitis C virus envelope E2 protein comprises 254 amino acids of said hepatitis C virus envelope E2 protein of SEQ ID NO:2.

In another embodiment of the method, the variant of the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 8, SEQ ID NO:3.

In another embodiment of the method, the inhibition of the attachment of hepatitis C virus onto cells is *in vitro*.

In yet another embodiment of the method, the compound is not previously known.

In a further embodiment of the method, the previously unknown compound is identified by said method.

The present invention also provides a composition comprising an effective amount of the compound identified by the method which is capable of inhibiting the interactions between hepatitis C virus envelope E2 protein and a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells.

The present invention also provides a pharmaceutical composition comprising an effective amount of the compound identified by the method which is capable of inhibiting the attachment of hepatitis C virus onto cells.

The present invention further provides a method for determining whether a compound can be used for treating or preventing hepatitis C virus infection in a subject, wherein said compound inhibits the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells so as to block the attachment of hepatitis C virus into cells, comprising (a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein or its variant under a suitable reaction conditions, (b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and (c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus onto a cell.

In one embodiment of the method, the subject is a human.

In another embodiment of the method, the compound can be administered orally or by injection.

In another embodiment of the method, the cells are liver cells.

In another embodiment of the method, the liver cells are human liver cells.

In another embodiment of the method, the hepatitis C virus E2 protein comprises amino acid sequence of Figure 7, SEQ ID NO:2.

In another embodiment of the method, the variant of the hepatitis C virus envelope E2 protein comprises 254 amino acids of said hepatitis C virus envelope E2 protein of SEQ ID NO:2.

In another embodiment of the method, the variant of the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 8, SEQ ID NO:3.

In another embodiment of the method, the cellular protein comprises Eo protein or its variant.

In another embodiment of the method, the Eo protein comprises the amino acid sequence of Figure 2, SEQ ID NO:1.

In another embodiment of the method, the variant of Eo protein comprises 120 amino acids of SEQ ID NO:1.

In another embodiment of the method, the variant of Eo protein comprises Eo1 protein having amino acids 1-120 of SEQ ID NO:1.

In yet another embodiment of the method, the compound is not previously known.

In a further embodiment of the method, the previously unknown compound is identified by said method.

As used herein, "subject" means any animal, including, for example, mice, rats, dogs, guinea pigs, ferrets, rabbits, and primates. In the preferred embodiment, the subject is a human.

"Cells" mean any cells, including, for example, lung cells, and kidney cells. In the preferred embodiment, the cells are liver cells. In a more preferred embodiment, the cells are human liver cells.

"Attachment" means the state of being firmly attached or bound through chemical or physical interactions or both. "Attachment of hepatitis C virus onto cells" means the hepatitis C virus being firmly attached or bound to the cell surface through the interaction between hepatitis C virus proteins, such as HCV E2 protein, and the HCV receptors located at the surface of the cells.

"Entry of HCV into cells" means the penetration of hepatitis C virus through the cell membrane into the cells from the cell surface.

"HCV replication" means HCV reproduction within the cells.

"Hepatitis C virus infection" comprises the attachment of hepatitis C virus to cell surface, the entry of hepatitis C virus into cells, the replication of hepatitis C virus within the cells, and the death or transformation of the cells.

"Agent" means any biological molecule which specifically bind to hepatitis C virus core protein. In one embodiment, the agent is a cellular protein.

As used herein, "suitable reaction conditions" means conditions under which an agent competitively binds to hepatitis C virus E2 protein or a variant thereof.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

Experimental Details

Yeast Two-Hybrid Screening: The yeast two-hybrid assay was performed using previously described methods (15, 16). Yeast two-hybrid screening was performed using the Matchmaker Two-Hybrid System 2 (Clontech). The library screened was a human liver Matchmaker cDNA (HL4002AB, Clontech).

Preparation of Hepatitis C Virus E2 protein construct for two-hybrid screening: The nucleotide sequence encoding amino acids 406-660, of hepatitis C virus E2 protein was amplified by polymerase chain reaction (17) with pHCV-1 as the template. The template for the polymerase chain reaction was pHCV (12) provided by Chiron Corporation. Full length HCV E2 is coded by amino acids 384-746. We therefore made a construct that would express a truncated form of HCV E2, excluding the hydrophobic segment. The amplified DNA was cloned into the GAL4 DNA binding domain fusion vector pAS2-1 to yield pAS2-1-HCV-E2.9 and library recombinants in the GAL4 activation domain fusion vector pACT2. Screening of 7 x 106 recombinants of a human liver cell cDNA library, with E2.9 as bait, in the yeast two-hybrid assay, led to the isolation of 5 positive clones three of which encoded portions of Eo.

To amplify the coding region from amino acid 384 to amino acid 661 of hepatitis C virus E2, oligonucleotides were synthesized based on the known sequence of pHCV (7, 12). The polymerase chain reaction primers had EcoRI and BamHI sites engineered into their 5' ends to facilitate cloning. The amplified product was cloned into the EcoRI and BamHI sites of plasmid PAS2-1 (Clontech). The identity of the construct was confirmed by restriction endonuclease mapping and DNA sequencing.

Isolation of positive plasmids from yeast: A patch of His^+, $lacZ^+$ yeast was incubated with lyticase (Sigma), followed by phenol:chloroform extraction in the presence of glass beads. After ethanol precipitation, E. *coli* HB101 was transformed with isolated yeast DNA, using electroporator II (Invitrogen). Transformants were plated on M9 minimum media plates. Library plasmids were purified with Wizard Plus Maxipreps DNA Purification system (Promega). Library plasmids were then transformed back into yeast Y190 (Clontech). His^+, $lacZ^+$ phenotypes were reconfirmed. Autonomous reporter gene activation was checked by co-transformation of the library plasmid with empty PAS2-1. pLAM5O-1 (Clontech), which expresses the coding region of lamin C, was used to check non-specific interactions. Plasmids encoding true positive interactors were sequenced.

DNA sequencing: DNA sequencing was performed at the DNA Sequence Facility of the Columbia University Comprehensive Cancer Center.

Results

We have screened 7×10^6 recombinant clones of a hepatocyte cDNA library using the yeast two-hybrid assay (15, 16) with a portion of hepatitis C virus E2 lacking its most hydrophobic, carboxyl-terminal domain. This screening led to the identification of only two true positive clones and both encoded a portion of a protein whose sequence is in the GenBank database (accession number D31767) but whose function is not known. The sequence of this portion, which we call Eo, is shown in Figure 2. The specificity of binding between Eo and a portion of hepatitis C virus envelope protein E2 in the yeast two-hybrid assay is shown in Figure 3.

Hydropathy analysis of the amino-acid sequence of Eo shows that it has a hydrophobic stretch that may be a putative transmembrane segment or membrane association domain (Figure 4). This suggests that Eo may be an integral membrane protein, which would be suspected for a cell surface virus receptor or co-receptor. To further characterize the binding of Eo to hepatitis C virus E2, two constructs of Eo were engineered, Eo1 and Eo2. Eo1 codes for amino acids 1-120 of Eo and Eo2 codes for amino acids 121-168 of Eo (Figure 5).

A yeast two-hybrid assay of Y190 cotransformed to express hepatitis C virus-E2 and Eo1 revealed a binding interaction, as did Eo (Figure 6). Eo2 did not bind to hepatitis C virus E2. This yeast two-hybrid Eo1-hepatitis C virus E2.9 binding interaction was confirmed in three independent binding assays. Hence, amino acids 1 to 120 of Eo protein binds to hepatitis C virus envelope E2, however, based on β-galactosidase activity, it appears weaker than the binding of all of Eo protein.

Discussion

The identification of proteins that bind to E1 and/or E2 can potentially function as inhibitors of viral attachment onto cells and their entry into cells, so as to prevent hepatitis C virus infection. This is a new way of preventing hepatitis C virus infection by blocking the HCV attachment onto cells and entry into cells through an external mechanism, i.e. identifying and using compounds that work outside of the cells and that target the envelope proteins E1 and/or E2 proteins. Inhibitors of HCV envelope proteins which bind to critical cellular proteins could also be useful therapeutic agents.

REFERENCES

1. Mamiya, N., and Worman, H. J. (1997) "Epidemiology, prevention, clinical features and therapy of hepatitis B, C and G." *Curr. Opin. Infect. Dis.* 10:3990-397;

2. Alter, M. J. (1997) "Epidemiology of hepatitis C." *Hepatology*, 26:62S-65S;

3. Choo, Q.-L., et al. (1989) "Isolation of a cDNA clone derived from blood-borne nonA, nonB viral hepatitis genome" *Science*, 244:359-362;

4. Kuo, G., et al. (1989) "An assay for circulating antibodies to a major etiological virus of human non-A, non-B hepatitis" *Science*, 244:359-363;

5. National Institutes of Health Consensus Development Conference Panel Statement (1997) "Management of Hepatitis C" *Hepatology*, 26:2S-10S;

6. Kato, N., et al. (1990) "Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis" *Proc. Natl. Acad. Sci. U.S.A.*, 87:9524-9528;

7. Choo, Q.-L., et al. (1991) "Genetic organization and diversity of the hepatitis C virus" *Proc. Natl. Acad. Sci. U.S.A.*, 88:2451-2455;

8. Okamoto, H., et al. (1991) "Nucleotide sequence of the genomic RNA hepatitis C virus isolated from a human carrier: comparison with reported isolates from

conserved and divergent regions" *J. Gen. Virol.*, 72:2697-6704;

9. Takamizawa, A., et al. (1991) "Structure and organization of the hepatitis C genome isolated from human carriers" *J. Viol.*, 65:1105-1113;

10. Reynolds, J. E., et al. (1995) "Unique features of internal initiation of hepatitis C virus RNA translation" *EMBO J.*, 14:6010-6020;

11. Fukushi, S., et al. (1997) "The sequence element of the internal ribosome entry site and a 25-kilodalton cellular protein contribute to efficient internal initiation of translation of hepatitis C virus RNA" *J. Virol.*, 71:1662-1666;

12. Selby, M. J., et al. (1993) "Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome" *J. Gen. Virol.*, 74:1103-1113;

13. Rosa, D., et al. (1996) "A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells" *Proc. Natl. Acad. Sci. U.S.A.*, 93:1759-1763;

14. Yi, M., et al. (1997) "Delineation of regions important for heterotrimeric association of hepatitis C virus E1 and E2" *Virology*, 231:119-129;

15. Fields, S., and Song, O. (1989) "A novel genetic system to detect protein-protein interactions" *Nature*, 340:245-246;

16. Chien, C., et al. (1991) "The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest" *Proc. Natl. Acad. Sci. U.S.A.*, 88:9578-9582;

17. Saiki, R. K., et al. (1988) "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase" *Science*, 239:487-491;

What is claimed is:

1. A method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of inhibiting the attachment of hepatitis C virus onto cells by specifically binding to the hepatitis C virus envelope E2 protein so as to treat or prevent hepatitis C virus infection.

2. The method of claim 1, wherein the agent is a polypeptide, a pseudo enzyme, a peptidomimetic compound, a nucleic acid, an antibody or its variant thereof.

3. The method of claim 1, wherein the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 7, SEQ ID NO:2.

4. The method of claim 1, wherein the variant of the hepatitis C virus envelope E2 protein comprises 254 amino acids of SEQ ID NO:2.

5. The method of claim 1, wherein the variant of the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 8, SEQ ID NO:3.

6. The method of claim 1, wherein the agent comprises a Eo protein or its variant.

7. The method of claim 6, wherein the Eo protein comprises the amino acid sequence of Figure 2, SEQ ID NO:1.

8. The method of claim 7, wherein the variant of Eo protein comprises 120 amino acids of SEQ ID NO:1.

9. The method of claim 7, wherein the variant of Eo protein comprises Eo1 protein having amino acids 1-120 of SEQ ID NO:1.

10. The method of claim 1, wherein the cells are liver cells.

11. The method of claim 10, wherein the liver cells are human liver cells.

12. A method of identifying a compound which can inhibit the attachment of hepatitis C virus onto cells by inhibiting the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells, comprising:

a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein under a suitable reaction conditions,

b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and

c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus onto cells.

13. The method of claim 12, wherein the cell is in a subject.

14. The method of claim 13, wherein the subject is a mammal.

15. The method of claim 13, wherein the subject is a human.

16. The method of claim 12, wherein the cellular protein comprises Eo protein or its variant.

17. The method of claim 16, wherein the Eo protein comprises the amino acid sequence of Figure 2, SEQ ID NO:1.

18. The method of claim 16, wherein the variant of Eo protein comprises 120 amino acids of SEQ ID NO:1.

19. The method of claim 16, wherein the variant of Eo protein comprises Eo1 having amino acids 1-120 of SEQ ID NO:1.

20. The method of claim 12, wherein the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 7, SEQ ID NO:2.

21. The method of claim 12, wherein the variant of hepatitis C virus envelope E2 protein comprises 254 amino acids of SEQ ID NO:2.

22. The method of claim 12, wherein the variant of hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 8, SEQ ID NO:2.

23. The method of claim 12, wherein the inhibition of the attachment of hepatitis C virus onto cells is in vitro.

24. The method of claim 12, wherein the compound is not previously known.

25. The compound identified by the method of claim 24.

26. A composition comprising an effective amount of the compound identified by the method of claim 12, wherein the compound is capable of inhibiting the interactions between hepatitis C virus envelope E2 protein and a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells.

27. A pharmaceutical composition comprising an effective amount of the compound identified by the method of claim 12, wherein the compound is capable of inhibiting the attachment of hepatitis C virus onto cells.

28. The method of claim 12, wherein the cells are liver cells.

29. The method of claim 28, wherein the liver cells are human liver cells.

30. A method for determining whether a compound can be used for treating or preventing hepatitis C virus infection in a subject, wherein said compound inhibits the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with

hepatitis C virus attachment onto cells and their entry into cells so as to block the attachment of hepatitis C virus onto cells, comprising:

a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein under a suitable reaction conditions,

b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and

c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus onto cells.

31. The method of claim 30, wherein the subject is a human.

32. The method of claim 30, wherein the compound can be administered orally or by injection.

33. The method of claim 30, wherein the cellular protein comprises Eo protein or its variant.

34. The method of claim 33, wherein the Eo protein comprises the amino acid sequence of Figure 2, SEQ ID NO:1.

35. The method of claim 33, wherein the variant of Eo

protein comprises 120 amino acids of SEQ ID NO:1.

36. The method of claim 33, wherein the variant of Eo protein comprises Eo1 protein having amino acids 1-120 of SEQ ID NO:1.

37. The method of claim 30, wherein the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 7, SEQ ID NO:2.

38. The method of claim 30, wherein the variant of the hepatitis C virus envelope E2 protein comprises 254 amino acids of Figure 7, SEQ ID NO:2.

39. The method of claim 30, wherein the variant of the hepatitis C virus envelope E2 protein comprises amino acid sequence of Figure 8, SEQ ID NO:3.

40. The method of claim 30, wherein the compound is not previously known.

41. The compound identified by the method of claim 40.

42. The method of claim 30, wherein the cells are liver cells.

43. The method of claim 2, wherein the liver cells are human liver cells.

HCV E2 PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

Abstract of the Disclosure

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of inhibiting the attachment of hepatitis C virus onto cells by specifically binding to the hepatitis C virus envelope E2 protein so as to treat or prevent hepatitis C virus infection. The present invention also provides a method of identifying a compound which can inhibit the attachment of hepatitis C virus onto cells and can treat or prevent hepatitis C virus infection in a subject by inhibiting the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells, comprising (a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein under a suitable reaction conditions, (b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and (c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus into a cell.

FIGURE 1



FIGURE 2 (SEQ ID NO:1)

MNSKGQYPTQPTYPVQPPGNPVYPQTLHLPQAPPYTDAPPAYSELYRPSFVHPGAATVPTMS
AAFPGASLYLPMAQSVAVGPLGSTIPMAYYPVGPIYPPGSTVLVEGGYDAGARFGAGATAGN
IPPPPPGCPPNAAQLAVMQGANVLVTQRKGNFFMGGSDGGYTIW

FIGURE 3



FIGURE 4



FIGURE 5



FIGURE 6


Yeast Two-Hybrid ß-galactosidase Assay
Eo
Eo1
Negative Control

FIGURE 7 (SEQ ID NO:2)

```
E T H V T G G S A G H T V S G F V S L L A P G A K Q N V Q L I
N T N G S W H L N S T A L N C N D S L N T G W L A G L F Y H H
K F N S S G C P E R L A S C R P L T D F D Q G W G P I S Y A N
G S G P D Q R P Y C W H Y P P K P C G I V P A K S V C G P V Y
C F T P S P V V V G T T D R S G A P T Y S W G E N D T D V F V
L N N T R P P L G N W F G C T W M N S T G F T K V C G A P P C
V I G G A G N N T L H C P T D C F R K H P D A T Y S R C G S G
P W I T P R C L V D Y P Y R L W H Y P C T I N Y T I F K I R M
Y V G G V E H R L E A A C N W T R G E R C D L E D R D R S E L
S P L L L T T T Q W Q V L P C S F T T L P A L S T G L I H L H
Q N I V D V Q Y L Y G V G S S I A S W A I K W E Y V V L L F L
L L A D A R V C S C L W M M L L I S Q A E A
```

FIGURE 8 (SEQ ID NO:3)

G A K Q N V Q L I N T N G S W H L N S T A L N C N D S L N T G
W L A G L F Y H H K F N S S G C P E R L A S C R P L T D F D Q
G W G P I S Y A N G S G P D Q R P Y C W H Y P P K P C G I V P
A K S V C G P V Y C F T P S P V V V G T T D R S G A P T Y S W
G E N D T D V F V L N N T R P P L G N W F G C T W M N S T G F
T K V C G A P P C V I G G A G N N T L H C P T D C F R K H P D
A T Y S R C G S G P W I T P R C L V D Y P Y R L W H Y P C T I
N Y T I F K I R M Y V G G V E H R L E A A C N W T R G E R C D
L E D R D R